How to buy AC Immune stock (ACIU)

AC Immune is a biotechnology business based in the US. AC Immune shares (ACIU) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.68 – a decrease of 8.22% over the previous week. AC Immune employs 133 staff and has a trailing 12-month revenue of around $41 million.

Our top picks for where to buy AC Immune stock

Buy AC Immune stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

AC Immune stock price (NASDAQ: ACIU)

Use our graph to track the performance of ACIU stocks over time.

AC Immune shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$2.68
52-week range	$2.25 - $5.14
50-day moving average more info button	$3.16
200-day moving average more info button	$3.34
Wall St. target price	$10.02
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.45

Is it a good time to buy AC Immune stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AC Immune price performance over time

Historical closes compared with the close of $2.68 from 2024-12-20

1 week (2024-12-16)	-8.22%
1 month (2024-11-22)	-20.71%
3 months (2024-09-23)	-26.78%
6 months (2024-06-20)	-34.47%

1 year (2023-12-20)	-33.83%
2 years (2022-12-23)	53.58%
3 years (2021-12-23)	5.39
5 years (2019-12-23)	8.2

AC Immune financials

Revenue TTM	$41 million
Operating margin TTM	28.52%
Gross profit TTM	$-56,401,000
Return on assets TTM	-12.04%
Return on equity TTM	-31.16%
Profit margin	-97.29%
Book value	$1.30
Market Capitalization more info button	$274.1 million

TTM: trailing 12 months

AC Immune share dividends

We're not expecting AC Immune to pay a dividend over the next 12 months.

AC Immune share price volatility

Over the last 12 months, AC Immune's shares have ranged in value from as little as $2.25 up to $5.14. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AC Immune's is 1.277. This would suggest that AC Immune's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

AC Immune overview

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24. 060 for the treatment of down syndrome-related AD; ACI-7104. 056, to treat Parkinson's disease; and ACI-35. 030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau.

Frequently asked questions

null
What percentage of AC Immune is owned by insiders or institutions?
Currently 21.683% of AC Immune shares are held by insiders and 28.82% by institutions. How many people work for AC Immune?
Latest data suggests 133 work at AC Immune. When does the fiscal year end for AC Immune?
AC Immune's fiscal year ends in December. Where is AC Immune based?
AC Immune's address is: Building B, Lausanne, Switzerland, 1015 What is AC Immune's ISIN number?
AC Immune's international securities identification number is: CH0329023102 What is AC Immune's CUSIP number?
AC Immune's Committee on Uniform Securities Identification Procedures number is: H00263105